Sex steroid hormones play an essential role in the control of homeostasis in the mammary gland. Although the involvement of progesterone in cellular proliferation and differentiation is well established, its exact role in the control of cell death still remains unclear. As dysregulation of the apoptotic process plays an important role in the pathogenesis of breast cancer, we investigated the regulation of apoptosis by progesterone in various breast cancer cell lines. Our results show that progesterone treatment protects against radiation-induced apoptosis. This prevention appears to be mediated by the progesterone receptor and is unrelated to p53 status. There is also no correlation with the intrinsic hormonal effect on cell proliferation, as the presence of cells in a particular phase of the cell cycle. Surprisingly, progesterone partly allows bypassing of the irradiation-induced growth arrest in G 2 /M in PgR þ cells, leading to an increase in cell proliferation after irradiation. One consequence of this effect is a higher rate of chromosome damage in these proliferating progesterone-treated cells compared to what is observed in untreated irradiated cells. We propose that progesterone, by inhibiting apoptosis and promoting the proliferation of cells with DNA damage, potentially facilitates the emergence of genetic mutations that may play a role in malignant transformation.
Introduction
Mammary gland development is a complex multiphase process whose different steps and functions are governed by numerous growth factors and hormones. Specifically, steroid hormones, estrogen and progesterone, are responsible for some of the most important physiological changes (Clarke and Sutherland, 1990) . Extensive investigations indicate that concerted action of these two hormones is pivotal in the control of mammary homeostasis.
Homeostasis in normal breast tissue is regulated by a delicate balance between cell proliferation, differentiation and apoptosis. Regulation of proliferation and differentiation and essential pathways involved in the physiological action of estrogen and progesterone in target tissues are well documented (Graham and Clarke, 1997; Sutherland et al., 1998) . Furthermore, several in vivo and in vitro reports clearly indicate that these hormones are also implicated in the control of cell loss by apoptosis (Kumar et al., 2000) , but these data remain controversial because, depending on the experimental model, both anti-and pro-apoptotic activity has been ascribed to each hormone (Flototto et al., 2001) .
Concerning the specific action of progesterone, an antiapoptotic effect is often observed in vivo during the menstrual cycle (Ferguson and Anderson, 1981) in uterus (Rotello et al., 1992) , corpus luteum (Juengel et al., 1993) and ovarian follicle (Luciano et al., 1994) . Using progesterone-release pellets implanted in the mouse mammary gland, a local protection against apoptosis during involution was also noted (Feng et al., 1995) .
In vitro, while an antiapoptotic activity was essentially described after progesterone treatment of endometrial cell lines (Pecci et al., 1997) , the results obtained in mammary cells were more contradictory. Pro- Wiley, 1998, 1999; Kandouz et al., 1999) , as well as antiapoptotic effects (Bardon et al., 1987; Alkhalaf et al., 2002) of progesterone and progestin treatment of breast cancer cell lines have been suggested. However, we recently showed that progesterone protected breast cancer cells against serum depletion-induced apoptosis (Ory et al., 2001 ). This protective effect was restricted to positive progesterone receptor (PgR þ ) cell lines and was observed with progesterone as well as medroxyprogesterone acetate (MPA), a synthetic progestin.
Although epidemiological studies, as well as experimental rodent models, indicate a strong relationship between breast cancer risk and sex steroid hormone exposure, the mechanism by which they act is poorly understood (Bernstein, 2002) . The well-documented proliferating effect of estrogen has contributed to the idea that it is the main steroid hormone implicated in the induction of cancer. There are now data indicating that progesterone could also play a pivotal role in tumorigenesis. It was shown that progestins have a role in the initiation and/or progression of rat and mouse mammary tumors (Lydon et al., 1999; Thordarson et al., 2001; Lanari and Molinolo, 2002) . However, clinical and epidemiological investigations remain controversial concerning the exact implication of progesterone in breast tumorigenesis in women, and the risk of use progestin in addition to estrogen in postmenopausal hormone replacement therapy is still being debated. As dysregulation of normal programmed cell death plays a crucial role in the induction, progression and maintenance of the neoplastic phenotype in the mammary gland, it is essential to understand better the relationships between progesterone treatment and propensity of cells to undergo apoptosis after DNA injury.
In order to know whether a direct hormonal modulation of apoptosis could be related to tumorigenesis, we studied the regulation of radiation-induced apoptosis by progesterone in mammary cells and its effect on the behavior of damaged cells. Using various breast cancer cell lines, we observed that progesterone protected cells against g-ray-induced apoptosis. This protection was restricted to the PgR þ cell lines and did not depend on p53 status, the intrinsic action of the hormone on cell proliferation and on the cell cycle distribution. Progesterone also increased the rate of cell proliferation after irradiation, cells showing a higher number of chromosome aberrations than cells treated by radiation alone. Our results indicated that progesterone modifies the cellular radiation sensitivity by inhibiting the apoptotic process, allowing the survival and proliferation of DNA-damaged cells, and thus potentially facilitates the emergence of genetic mutations that may play a part in malignant transformation.
Results

Progesterone inhibits radiation-induced apoptosis in T-47D breast cancer cell line
Modulation of radiation sensitivity by progesterone was first studied using T-47D cells, a well-characterized cell line expressing PgR. As seen in Figure 1a , 7 days after irradiation, for doses Z4 Gy (the threshold from which cell death becomes significant), the percentage of cell death was lower in cells treated with 10 À8 M progesterone, compared to cells treated by radiation alone (Àpg). This protection remained of the same order when the cells were treated with progesterone 2 days before irradiation (dÀ2) or on the day of irradiation (d0). After a 10 Gy radiation exposure, a similar protection was observed after treatment with the synthetic progestin MPA (1-100 nM) when compared with the protection observed after a progesterone treatment (10 and 100 nM) (Figure 1b) . In the present work, we used MPA, a synthetic progestin, instead of natural progesterone because of its greater stability in culture medium.
As previously shown (Butt et al., 2000) , we checked that in T-47D cells radiation induced cell death via an apoptotic process. Using Hoechst staining, we observed cells with clear chromatin condensation and apoptotic bodies after g-ray treatment (Figure 2a) . In order to compare the percentage of apoptotic cells with or without progesterone treatment, apoptosis was analysed by in situ TUNEL assay (Figure 2b ). At 5-7 days after irradiation, apoptotic cells accounted for 6-12% in control cells and 1.5-3% in progesterone-treated cells. The percentages of dead cells detected by this technique were lower than after trypan blue staining, but the TUNEL assay only detects cells with cleaved DNA at a given time, while trypan blue staining permitted scoring of the accumulation of cell cadavers.
These observations indicated that progesterone protects cells against radiation-induced apoptosis.
Effect of progesterone treatment on growth and radiation sensitivity of different human breast cancer cell lines Since we did not know if the protective effect of progesterone against apoptosis was a general phenomenon or was specific and restricted to the T-47D cell line, we studied the modulation of radiation sensitivity by Concentrations used for each treatment were 1, 10 or 100 nM. Discrimination between viable and dead cells was performed after trypan blue staining. Results correspond to the mean7standard deviation of at least two independent measurements progesterone in a panel of six human breast cancer cell lines. Some characteristics of the different cell lines are summarized in Table 1 . For PgRÀ cell lines (BT-20, HBL-100 and MDA-MB-231), we observed that, without irradiation, a progesterone treatment failed to induce any alteration of proliferation over 7 days (Figure 3a-c) .
Rates of radiation-induced cell death were also not significantly modified by progesterone (added 2 days before irradiation or on the day of irradiation) in 4-or 10 Gy-irradiated PgRÀ cells (Figure 4a-c) .
In contrast to PgRÀ cell lines, we observed in PgR þ cell lines (T-47D, ZR-75-1, H-466B) that progesterone treatment leads to the alteration of both proliferation (Figure 3d -f) and radiation-induced cell death ( Figure  4d-f ). An antiproliferative effect of progesterone was seen in two cell lines: T-47D and ZR-75-1 (Figure 3d , e), while progesterone slightly stimulated the proliferation of H-466B cells (Figure 3f) . In all cases, we did not observe modification of cell viability after hormonal treatment (Figure 3d-f) . Following irradiation, a progesterone-mediated protective effect against radiation-induced cell death was shown in all PgR þ cell lines whatever their intrinsic radiosensitivity, since it was observed after 4 and 10 Gy-irradiation in T-47D (the most radiation-sensitive cell line) and H-466B cells, and only after 10 Gy irradiation in the most radiationresistant cell line: ZR-75-1. As previously shown in T-47D cells (Figure 1) , the same protective effect was observed whether progesterone was added 2 days before irradiation or on the day of irradiation (Figure 4 : þ pg dÀ2 and þ pg d0).
To ensure that progesterone action was mediated by PgR, irradiated T-47D cells were co-treated with 10 nM progesterone and 10-1000 nM mifepristone/RU 486, an antagonist ligand (Figure 5a ). We observed that mifepristone counteracted the progesterone-mediated effect in a concentration-dependent manner, treatment with mifepristone alone failing to induce any protection. These data strongly suggested that progesterone protection specifically acts through PgR. The progesterone-mediated protection against apoptosis seemed to be unrelated to the action of progesterone on proliferation since it inhibited proliferation in 2 PgR þ cell lines (T-47D and ZR-75-1), whereas it enhanced proliferation in the third PgR þ cell line (H-466B) (Figure 3d -f). Mifepristone treatment also indicated that there was no relationship between the two phenomena, since mifepristone alone inhibited T-47D proliferation (Figure 5b ), but had no effect on radiation-induced cell death ( Figure 5a ).
The progesterone-mediated protection against apoptosis was independent of p53 status, since T-47D and H-466B cells expressed a mutant p53 protein, while ZR-75-1 cells expressed a functional wild-type p53 protein (Table 1) .
To sum up, the protective effect of progesterone against radiation-induced cell death appeared to be mediated by PgR independently of p53 status and of the hormonal action on cellular proliferation.
Effect of progesterone treatment and of irradiation on the cell cycle
Since previous studies showed that progesterone treatment of T-47D cells led to an accumulation of cells in the G 0 /G 1 phase of the cell cycle, we decided to study whether the protective effect of progesterone against apoptosis could be cell cycle-dependent and/or related to the presence of cells at a specific checkpoint at the time of treatment. As previously described, progesterone treatment of T-47D cells led to growth inhibition (Ory et al., 2001; Lebeau et al., 2002) . On the one hand, the percentage of cells in the G 0 /G 1 phase of the cell cycle increased 24 h after progesterone addition. At the same time, we observed a decrease in the percentage of cells in the S and G 2 /M phases ( Figure 6a ). This cell cycle arrest persisted for 7 days and was still observed 14 days after the treatment (data not shown). On the other hand, after irradiation and without progesterone, we observed a growth arrest, associated with a marked increase in the percentage of cells in G 2 /M phase (Figure 6b : Àpg). The percentage of cells accumulated in G 2 /M phase exceeded 80% after 10 Gy irradiation (60% following a 4 Gy irradiation: data not shown). The G 2 /M accumulation persisted up to 7 days after treatment (data not shown).
Following radiation and progesterone treatment, the cell cycle distribution of T-47D cells was more complex and depended on when the progesterone was added ( Apoptosis inhibition by progesterone G Vares et al stayed in G 0 /G 1 after irradiation. In the case of simultaneous irradiation and progesterone treatment ( þ pg d0), the effect on cell cycle distribution was intermediate, cells equally accumulated both in G 0 /G 1 and G 2 /M phases. These data suggested that the protective effect against radiation-induced apoptosis is not related to modulation of radiosensitivity according to a particular cell cycle distribution, since resistance to apoptosis was observed whenever progesterone treatment was done (dÀ2 or d0). This assumption was reinforced by analysing the cell cycle distribution in the other PgR þ cell lines ( Figure  6c -f). Whereas we observed a similar pattern of distribution for ZR-75-1 cells compared to T-47D cells, the situation was quite different for H-466B cells, since we observed an increased percentage of cells in S and G 2 /M phases. These results are in agreement regarding data obtained on cell proliferation after progesterone treatment (Figure 3d-f) . After irradiation, cells were accumulated both in G 0 /G 1 and G 2 /M phases whether progesterone was added or not. No particular accumulation in any phase of the cell cycle could be strongly associated with the protection against apoptosis. Taken together, these results strongly suggested that apoptosis inhibition was independent of cell cycle distribution or presence of cells at a specific cell cycle checkpoint.
Effect of progesterone on cell division rate after irradiation
In order to know whether the protective effect of progesterone against apoptosis could be related to an effect on the capacity of irradiated cells to proliferate, we analysed the number of cells able to divide after treatment. PgR þ cells were treated with cytochalasin-B which blocks cytokinesis and thus leads to accumulation of multinucleated cells. The number of multinucleated cells represents the capacity of cells to divide throughout contact with cytochalasin-B (24 h). Figure 7a shows the index of proliferation (cf. Materials and methods) of T-47D cells after a 6 Gy-radiation exposure with or without progesterone treatment. With progesterone, we observed a significant increase in the index of proliferation compared to radiation alone. While progesterone treatment alone blocked cellular division, as illustrated in Figure 3d , after irradiation it increased the capacity of T-47D cells to divide.
An increase in proliferation was also observed for ZR-75-1 and H-466B irradiated cells after progesterone treatment (Figure 7c ,e), this increase being lower than for T-47D. It is interesting to note that ZR-75-1 and H-466B cells showed a higher index of proliferation than T-47D. This can be explained by the differences in doubling time of each cell line: 42-48 h for T-47D and 20-26 h for ZR-75-1 and H-466B. As a result, the index of proliferation for these two cell lines was made up essentially of binucleated cells but also of tri-and quadrinucleated cells (i.e. cells performing more than one doubling in 24 h), but only of binucleated cells for T-47D cells. We observed that progesterone may enhance the rate of tri-and quadrinucleated cells up to five times for H-466B cells and up to two times for ZR-75-1 cells (data not shown).
In conclusion, these results demonstrated that progesterone could in part counterbalance the irradiationinduced growth arrest in PgR þ cells.
Estimation of the frequency of chromosome aberrations by scoring micronuclei in dividing cells
In order to establish whether cells able to proliferate contain chromosomal abnormalities, we studied the frequency of micronuclei in multinucleated cells after irradiation with or without progesterone treatment. The usefulness of micronuclei as markers for cytogenetic damage has been described in numerous studies, the frequency of micronuclei being representative of the frequency of chromosomal damage within cells , were determined after 6 Gy irradiation of T-47D cells. Cells were analyzed every 24 h for 4 days after a 24-h treatment with cytochalasin-B. Results correspond to the mean7standard deviation of four to six independent measurements. Statistical differences were determined using Student's t-test; *Po0.05 compared with untreated cells (Àpg) few chromosome abnormalities. We observed that, between 24 and 96 h after irradiation, progesterone treatment led to an increased number both of dividing cells containing micronuclei and an increased number of micronuclei per multinucleated cell. Interestingly, after irradiation, the greatest difference in micronuclei frequency between progesterone-treated and untreated cells was observed between 24 and 48 h, which also corresponds to the greatest difference in the proliferative rate (Figure 7a) . The difference in the frequency of chromosome damage per multinucleated cell between progesterone-treated and untreated irradiated cells slightly decreased, but remained statistically different for at least 96 h after irradiation.
A global increase in the frequency of micronuclei per multinucleated cell after progesterone treatment was also observed for the two other PgR þ cell lines: H-466B and ZR-75-1 (Figure 7d, f) . These increases were lower than for T-47D cells.
Taken together, these results indicate that progesterone increases the frequency of chromosome aberrations in irradiated cells by inhibiting apoptosis and promoting the proliferation of cells with DNA damage.
Expression of apoptosis-related genes
Previously, we have described a protective effect of progestin against serum depletion-induced apoptosis, and studied the expression of apoptosis-related genes potentially implicated in this protection (Ory et al., 2001) . In order to know if these genes could be implicated in the regulation of radiation-induced apoptosis by progesterone, we have analysed the expression of these genes using real-time quantitative PCR, for 6 days after 6 Gy irradiation of T-47D cells treated ( þ pg dÀ2) or not (Àpg) with progesterone. We analysed genes coding for antiapoptotic proteins: BCL2, BCLX-L, MCL1, DAD1 and BAG1, or pro-apoptotic proteins: BAX, BAK1, BCLX-S, BIM EL, HRK (hara-kiri), REQ (requiem), CASP3 and CASP7. In agreement with the protective effect, the expression of pro-apoptotic HRK mRNA was strongly upregulated after irradiation and this overexpression was in part prevented by the progesterone treatment (Figure 8 ). We also observed the well-described downregulation of BCL2 mRNA and upregulation of both BCLX-L and BCLX-S mRNAs (with an unchanged ratio between the two isoforms) after progesterone treatment. However, these results appeared to be related to the cellular response to the progesterone treatment itself, independently of the protection against apoptosis. The other mRNAs tested presented similar expression between progesteronetreated and untreated irradiated cells (data not shown).
Discussion
In the present study, we show that progesterone is an important factor in changing the sensitivity of breast cancer cell lines to ionizing radiation. Our results indicate that progesterone protects cells against radiationinduced apoptosis, and stimulates proliferation of irradiated cells with chromosomal abnormalities, both protection and stimulation only being observed in PgR þ cell lines. The latter point and the observation that mifepristone/RU 486 counterbalances the progesterone-mediated protection indicate that the modulation of radiosensitivity induced by progesterone is more related to responses to the hormone via PgR binding mechanisms in these cells than to pathways involving other receptors or to nongenomic pathways.
The role of progesterone in the regulation of apoptosis in mammary cell lines is still unclear since both anti-and pro-apoptotic activities have been described. In studies showing that progesterone mediated growth inhibition via apoptosis induction (Formby and Wiley, 1998; Gompel et al., 2000) , overall the rate of apoptosis was very low and, more importantly, the hormone was used at a high and nonphysiological concentration. Using physiological ranges of progesterone concentrations (1-100 nM), we and others (Ory et al., 2001; Alkhalaf et al., 2002) showed a significant protective effect of progesterone against apoptosis. Moreover, in standard conditions of culture, we failed to observe any difference in the rate of cell death in unirradiated cells with or without progesterone treatment (Figure 3) .
The protective effect against apoptosis appeared to be unrelated to the intrinsic effect of progesterone on cell proliferation, since it is observed in the three PgR þ cell lines although the hormone inhibited proliferation in T-47D and ZR-75-1 cells while it activated proliferation in H-466B cells (Figure 3d-f) . Numerous data suggested that the apparently paradoxical dual proliferative and antiproliferative action of progesterone could be explained by a crosstalk between PgR and multiple signaling pathways in the breast (Lange et al., 1999) . These studies, using T-47D cells, described a biphasic effect of the hormone, which consists of a transient acceleration of the cell cycle followed by a long-term growth inhibition and arrest in G 1 phase (Groshong Figure 8 Time course of HRK mRNA expression after 6 Gy irradiation of T-47D cells. mRNA expression was normalized as function of 18S ribosomal RNA expression. The basal level of expression at day 0 was fixed at 1. Each value corresponds to the mean value of three independent PCRs performed from two independent cDNA preparations. Error bars correspond to standard deviation et al., 1997; Musgrove et al., 1998; Owen et al., 1998; Lange et al., 1999) . In this model, progesterone can advance cells to a G 1 checkpoint where the fate of the cells could be determined by crosstalk between progesterone and growth or differentiating factors. So, the ultimate physiological effect of progesterone is a result of composite signal pathways. This could explain how in vivo progesterone can be both proliferative and antiproliferative, and why our three cell lines present different responses to a continuous hormonal treatment. Depending on growth factors/cytokine-signaling pathways, which are specific to and different in each cell line, the cell fate induced by progesterone may be different: growth inhibition or proliferation. In conditions similar to ours, other studies also indicated that progestininduced growth inhibition coincides with enhancement of differentiation in various mammary cell lines, including T-47D (Kester et al., 1997; Alkhalaf et al., 2002; Lin et al., 2003) . In all cases, all these hormonal effects on proliferation and/or differentiation appear to be completely independent of the protective effect of the hormone against radiation-induced apoptosis. This is reinforced by our present data which show that mifepristone alone also inhibited proliferation of T-47D cells but had no effect on radiation-induced apoptosis.
Data indicating that the protective effect of progesterone against apoptosis is not dependent on the intrinsic control of cell proliferation are also strengthened by cell cycle analysis (Figure 6 ). On the one hand, depending on the time lapse between progesterone treatment and radiation, 2 days before or on the same day (dÀ2 or d0), T-47D cells were not similarly distributed within the phases of the cell cycle at the time of irradiation (dÀ2: 490% in G 0 /G 1 , d0: classical cell cycle distribution) and the effects of radiation on the cell cycle were different (dÀ2: 80% in G 0 /G 1 or d0: 40-60% in G 0 /G 1 and G 2 /M). Similar results were observed for ZR-75-1 cells, but with less marked blockages in cell cycle phases. On the other hand, H-466B cells were less accumulated in G 0 /G 1 phases at the time of irradiation after progesterone treatment, and both blockages in G 0 / G 1 and G 2 /M occurred after irradiation independently of the hormonal treatment. However, in all conditions and for all PgR þ cell lines, we observed a protective effect of progesterone. So there is no direct relationship between the protective effect of progesterone and cell cycle distribution after irradiation.
One essential effect of progesterone was shown to be a significant inhibition of the irradiation-induced growth arrest. After irradiation, T-47D cells accumulated in G 2 / M phase (Figure 6b) , and the index of proliferation remained low for at least 4 days (Figure 7a ). When T-47D cells were treated with progesterone, the accumulation in G 2 /M phase was lower if progesterone was added at d0 and nonexistent when it was added at dÀ2 ( Figure 6 ). In the latter case, progesterone increased the proportion of dividing cells (compared to radiation alone) for at least 4 days after radiation (Figure 7a ). This increase in the index of proliferation was significant but lower after progesterone treatment of ZR-75-1 and H-466B cells (Figure 7c, e) . In agreement with this, the decrease in the number of cells accumulated in G 2 /M was also observed for ZR-75-1 cells (Figure 6d ) and H-466B cells (Figure 6f) . So, progesterone prevents or avoids the initial g-irradiation-induced growth arrest in G 2 /M phase, and allows cells to divide.
This bypass of the G 2 /M checkpoint could be the consequence of the initial transient acceleration through the first mitotic cell cycle observed in the progesterone biphasic effect model described above. This effect was shown to be mediated by the sequential induction of cyclins D1, D3, E, A and B, activation of cyclin-CDK2 and -CDK4 complexes and induction of c-myc and c-fos (Lange et al., 1999) . Bypass of the G 2 /M checkpoint also occurred when progesterone treatment was performed 2 days before irradiation (i.e. when cells were already accumulated in G 0 /G 1 phase), suggesting that irradiation should probably modify the cell context and sensitize cells to a second stimulus by progesterone and/or by other factors.
Lastly, we observed after progesterone treatment that dividing irradiated cells contained an increased level of chromosome abnormalities (Figure 7b, d, f) . Overall, the final progesterone effect is a combination of both an increased number of proliferating cells and an increased rate of DNA damage within cells. This effect is not restricted to the first wave of cells able to divide since it is observed (1) up to 4 days after irradiation, the higher level of proliferation occurring late could be due to cells performing a second round of division or alternatively to delayed first cell divisions, (2) for cell lines growing quickly (ZR-75-1 and H-466B), the rate of cells performing more than one round of division per 24 h was strongly enhanced by progesterone treatment. Anyway, for T-47D cells, over the period of 4 days, the sums of percentages of proliferating cells and numbers of micronuclei per dividing cell reached, respectively, a 2-and a 1.6-fold increase, compared to sums obtained for radiation alone, leading to a global increase of more than threefold in the number of micronuclei. For ZR-75-1 and H-466B cells, this global increase is, respectively, 41.4 and 41.5. Kao et al. (2001) showed that DNA damage-induced G 2 delay was strongly associated with DNA repair activity in human cancer cells. We can hypothesize that, after irradiation, progesterone leads to the inhibition of the G 2 checkpoint that normally arrests the cell cycle and permits cells to repair DNA damage and/or to undergo apoptosis if the level of unrepaired DNA is too high. So, progesterone treatment, by avoiding radiationinduced growth arrest and preventing apoptosis, may promote the proliferation of cells carrying numerous chromosomal rearrangements. Our results are sustained by the increased number of sister chromatid exchanges (a sensitive indicator of DNA damage) previously observed in newborns after progesterone treatment during pregnancy (Lukic and Barjaktarovic, 1987) , as well as in lymphocytes of women treated with oral contraceptives (Biri et al., 2002) .
The molecular mechanisms underlying progesterone modulation of apoptosis remain poorly documented.
In vivo studies indicate that regulation of BCL2 family proteins is observed in the involuting mouse mammary glands (Heermeier et al., 1996; Metcalfe et al., 1999; Schorr et al., 1999) . Hormonal regulation of bcl-2 expression in the human mammary epithelium was also suggested (Sabourin et al., 1994) . In a previous report, we analysed the expression of apoptosis-related genes, especially bcl-2 family members, in relation with the progesterone-mediated protection against serum starvation-induced apoptosis. We found that expression of mRNAs coding for two pro-apoptotic proteins, HRK and BAK1, were upregulated after apoptosis induction in PgR þ cell lines and inhibited when cells were protected against serum starvation-induced apoptosis after progestin treatment. In the present work, after irradiation, among the 13 apoptosis-related genes analysed, only HRK was found to be a marker of apoptosis in T-47D cells (Figure 8 ). However, even if the expression of several other genes was modified after irradiation, the regulation of their expression was not correlated with progesterone-mediated protection against apoptosis. Since bcl-2 family gene expression does not seem to be tightly regulated by progesterone in response to irradiation, our results strongly suggest that the molecular mechanisms underlying this protective effect may be different from those implicated in the control of apoptosis during involution in the mammary gland. Furthermore, our results were also partly different from what we observed when progesterone protected cells against serum starvation-induced apoptosis, indicating that implicated pathway(s) should be partly specific to radiation-induced apoptosis.
Several reports indicate that progesterone also plays a role in the regulation of cell signaling pathways potentially implicated in the control of the apoptotic process: activation of the PI3/Akt pathway associated with a protection against apoptosis (Alkhalaf et al., 2002) , activation of the c-Src/p21/MAP kinase signal transducing pathway (Migliaccio et al., 1998; Lange et al., 1999) , and others. Progestins may also regulate p53 in various contexts: progesterone may decrease the expression of p53 in experimental models where it presents a proliferative activity (Hurd et al., 1995) , or it may inhibit cell growth and apoptosis via direct upregulation of p53 in ovarian cells (Murdoch and Van Kirk, 2002) . The tumor-suppressor gene TP53 plays a pivotal role in surveillance, repair of radiation-induced DNA damage as well as in the modulation of apoptosis (Levine, 1997) . In our model, we observed the same protection against apoptosis by progesterone in p53 wild-type cell line (ZR-75-1) and in p53-mutated cell lines (T-47D and H-466B) (Figure 4) . The mutated phenotype of p53 in T-47D cells was confirmed by the observed loss of the G 1 /S restriction checkpoint, leading to accumulation in G 2 /M after irradiation. However, although our results strongly suggest that the mutational status of p53 does not seem to influence the progesterone-mediated protection against apoptosis, this does not mean that it is p53-independent since it was shown that progesterone modulates the activity of p53 in T-47D cells (Kester et al., 2003) . The p53 protein also mediates repair of double-strand DNA breaks following g-irradiation, so the relations between progesterone and increased rate of chromosome damage within dividing cells after radiation could be linked to a modulation of DNA repair efficiency. Progesterone also regulates p21 via p53-dependent and independent mechanisms, this protein being essential for the control of proliferation but also for differentiation and apoptosis (Shim et al., 1996; Owen et al., 1998; Lange et al., 1999; Kester et al., 2003) . These data indicate that although the precise cellular and molecular mechanisms involved in the protection against apoptosis mediated by progesterone remain unknown, progesterone may potentially regulate apoptosis in different ways, depending on the cellular model as well as the way of inducing of apoptosis.
In conclusion, we have demonstrated that progesterone may protect breast cancer cell lines against radiation-induced apoptosis. A crucial consequence of progesterone treatment is an increased number of surviving and proliferating cells containing much chromosome damage. Apoptosis of abnormal cells at the early stages of carcinogenesis may be one mechanism by which women are protected from breast cancer. Consequently, failure of damaged cells to undergo apoptosis may contribute to the development of cancer, since it allows the survival of DNA-damaged cells. In view of the current debate concerning the potentially increased risk of breast cancer in women using progesterone in hormone replacement therapy, this may represent an important area for further study.
Materials and methods
Cell cultures
T-47D, H-466B, ZR-75-1, BT-20, MDA-MB-231 and HBL-100 cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). All cell lines, except for BT-20 cells, were maintained in Dulbecco's modified Eagle medium (DMEM) 4.5 g/l glucose, 0.11 g/l sodium pyruvate, glutamate (GlutaMAX 1t) and pyridoxine, supplemented with 5% fetal calf serum, penicillin, streptomycin and amphotericin B (antibiotic-antimycotic mix) (all from Life Technologies, France). For BT-20 cells, DMEM was replaced by RPMI 1640 medium with GlutaMAX 1t, 20 mM HEPES and 2.5 mM sodium pyruvate were added. Cultures were grown in 5% CO 2 at 95% humidity.
Irradiation and hormone treatment
Cells were plated 72 h prior to irradiation. At day 0 (d0), cells were irradiated in a serum-free medium, using a 137 Cs irradiation unit at doses ranging from 0.5 to 15 Gy (gray) and a dose rate of B2 Gy/min, and then washed in medium and incubated with fresh medium. Hormone treatments were performed two days (dÀ2) before irradiation or on the day of irradiation (d0).
MPA (6a-methyl-17a-hydroxyprogesterone acetate), a progesterone agonist, natural progesterone and mifepristone/RU 486 were from Sigma (France). Hormones were dissolved in absolute ethanol and 1000 Â solutions were prepared. Control cells were treated with the same final concentration of ethanol.
Since MPA is highly stable in the medium at 371C, no renewal was performed after day 0. T-47D cells were treated with 10 nM MPA; the other cell lines were treated with 100 nM MPA. For natural progesterone treatment, T-47D cells were treated daily with concentrations ranging from to 10 to 100 nM. Mifepristone (10-1000 nM) displays a high stability, so the treatments were performed once on day 0 without renewal.
Proliferation, survival and apoptosis
Cell proliferation and survival analyses were performed in two or more separate experiments, by scoring at least 200 cells each time. Discrimination between viable and dead cells (including dead cells in the supernatant) was performed after trypan blue staining.
Apoptosis was analysed in two separate experiments by scoring at least 500 cytospun cells. Cells were fixed with 4% paraformaldehyde in PBS, stained with 2 mg/ml Hoechst dye 33258 (Sigma, France) diluted in PBS, and analysed by fluorescence microscopy. Cells presenting clear chromatin condensation were scored as apoptosis-positive. To confirm Hoechst staining, apoptosis was analysed by in situ TUNEL assay (APO-BrdUt kit, Becton Dickinson, France). For both apoptosis techniques, around 25 000 cells (including cells in the supernatant) were cytospun onto glass slides (300 r.p.m. for 5 min), air dried for 24 h at room temperature, and stored at À201C until used.
Flow cytometry
For cell cycle analysis, cells were trypsinized and harvested by centrifugation at 1400 r.p.m. for 10 min, washed in PBS, fixed in 70% cold ethanol and stored at À201C. Before analysis, cells were washed in PBS and stained in PBS containing 25 mg/ml propidium iodide (Sigma, France) and 50 mg/ml RNase A (Roche Diagnostics, France) for 30 min at 371C. Samples were analysed using a FACScalibur flow cytometer (Becton Dickinson, France) on at least 20 000 cells. Cellular debris, fixation artifacts and doublets were gated out with FL2-area and FL2-width parameters. Cell cycle was analysed using Modfit software (Verity, Becton Dickinson, France).
Cytochalasin-B blocked assay and micronuclei scoring
Multinucleated cells and micronuclei were scored according to the cytochalasin-B blocked assay (Fenech and Morley, 1985) . After 24-h treatment with 1.25 mg/ml of cytochalasin-B (Sigma, France) in the culture medium, cells were trypsinized and centrifuged at 400 r.p.m. for 5 min, submitted to a hypotonic stress in 0.075 mM KCl for 20 s, and finally fixed three times in methanol/acetic acid (3V/1 V) (the first bath for 20 minutes and then time is not crucial) (one centrifugation at 400 r.p.m. for 10 min was done between each fixation). Fixed cells were then dropped on slides, air dried for at least 24 h, and stained with eosin-hematoxylin-giemsa. For each point, four to six independent measurements were performed, and the number of multinucleated cells (bi-, tri-, quadri-nucleated cells (BN, TN, QN)) (MNC) was evaluated in a total of 5000-10 000 cells. The index of proliferation was calculated as (2BN þ 3TN þ 4QN )/total number of cells. The frequency of micronuclei (MN) was scored in a total of 1000-3000 multinucleated cells.
RNA extraction and semiquantitative RT-PCR
For the first-strand cDNA synthesis, 1 mg of total RNA, extracted with RNA Plus (Quantum Biotechnologies, France), was mixed with 1 mM of random primer p(dN) 6 (Roche Diagnostic, France) and 250 mM dNTP (Life Technologies, France) in a 1 Â reverse buffer (6.7. mM MgCl 2 , 67 mM TrisHCl (pH 8.8), 16.6 mM (NH 4 ) 2 SO 4 ), then incubated for 5 min at 651C and placed on ice before adding 200 units of M-MLV (Life Technologies, France) in a final volume of 20 ml and further incubated for 30 min at 421C, followed by incubation for 3 min at 721C to inactivate reverse transcriptase. Primer sets used and PCR conditions such as MgCl 2 concentration, annealing temperature and number of cycles were optimized for each gene in order to perform PCR in the linear part of amplification and were previously described (Ory et al., 2001) .
